HK1114612A1 - Pyridine derivative and pyrimidine derivative (3) - Google Patents
Pyridine derivative and pyrimidine derivative (3)Info
- Publication number
- HK1114612A1 HK1114612A1 HK08110122.2A HK08110122A HK1114612A1 HK 1114612 A1 HK1114612 A1 HK 1114612A1 HK 08110122 A HK08110122 A HK 08110122A HK 1114612 A1 HK1114612 A1 HK 1114612A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- derivative
- pyrimidine
- pyridine
- pyridine derivative
- pyrimidine derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71067105P | 2005-08-24 | 2005-08-24 | |
| PCT/JP2006/316331 WO2007023768A1 (ja) | 2005-08-24 | 2006-08-21 | 新規ピリジン誘導体およびピリミジン誘導体（３） |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1114612A1 true HK1114612A1 (en) | 2008-11-07 |
Family
ID=37771513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08110122.2A HK1114612A1 (en) | 2005-08-24 | 2008-09-11 | Pyridine derivative and pyrimidine derivative (3) |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7855290B2 (zh) |
| EP (1) | EP1889836B1 (zh) |
| JP (1) | JP4077028B2 (zh) |
| KR (1) | KR100950737B1 (zh) |
| CN (1) | CN101198590B (zh) |
| AU (1) | AU2006282456C1 (zh) |
| BR (1) | BRPI0616799B8 (zh) |
| CA (1) | CA2605854C (zh) |
| DK (1) | DK1889836T3 (zh) |
| ES (1) | ES2424651T3 (zh) |
| HK (1) | HK1114612A1 (zh) |
| HR (1) | HRP20130719T1 (zh) |
| IL (1) | IL188670A (zh) |
| JO (1) | JO2925B1 (zh) |
| MY (1) | MY140873A (zh) |
| NO (1) | NO20080460L (zh) |
| NZ (1) | NZ566793A (zh) |
| PL (1) | PL1889836T3 (zh) |
| PT (1) | PT1889836E (zh) |
| RS (1) | RS52902B (zh) |
| RU (1) | RU2362771C1 (zh) |
| SI (1) | SI1889836T1 (zh) |
| TW (1) | TWI377198B (zh) |
| WO (1) | WO2007023768A1 (zh) |
| ZA (1) | ZA200709572B (zh) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070270421A1 (en) | 2004-02-27 | 2007-11-22 | Tomohiro Matsushima | Novel pyridine Derivative and Pyrimidine Derivative (1) |
| ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| SI1889836T1 (sl) | 2005-08-24 | 2013-10-30 | Eisai R&D Management Co., Ltd. | Nov derivat piridina in derivat piridina (3) |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용 |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| JP5190365B2 (ja) * | 2006-08-23 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の塩またはその結晶およびそれらの製造方法 |
| EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US7790885B2 (en) * | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| WO2008049855A2 (en) * | 2006-10-27 | 2008-05-02 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| CA2679602A1 (en) * | 2007-02-23 | 2008-08-28 | Eisai R&D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| EP2218712B1 (en) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| KR101608096B1 (ko) | 2008-01-23 | 2016-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | ４-피리디논 화합물 및 암을 위한 그의 용도 |
| JP2009203226A (ja) * | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
| US20100311972A1 (en) * | 2008-02-18 | 2010-12-09 | Mitsuo Nagai | Method for producing phenoxypyridine derivative |
| EP2532657B9 (en) | 2008-10-14 | 2017-04-19 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| WO2010064300A1 (ja) * | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| CA2746354A1 (en) | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| AU2010229147B2 (en) | 2009-03-21 | 2012-07-05 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| KR20130109943A (ko) | 2010-04-29 | 2013-10-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체 |
| JP5898074B2 (ja) | 2010-06-25 | 2016-04-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| TWI545115B (zh) * | 2010-11-01 | 2016-08-11 | 阿維拉製藥公司 | 雜環化合物及其用途 |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| RU2590158C2 (ru) | 2011-03-29 | 2016-07-10 | ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. | Способ получения производного феноксипиридина |
| CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| CN103509024B (zh) * | 2012-06-28 | 2015-10-28 | 上海医药工业研究院 | 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用 |
| WO2014075754A1 (en) * | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | 3-aminocyclopentane carboxamide derivatives |
| CN102964308B (zh) * | 2012-11-30 | 2015-03-18 | 中国药科大学 | 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| WO2014185540A1 (en) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
| WO2018108954A1 (en) * | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol |
| LT3802517T (lt) | 2018-06-07 | 2023-03-10 | Idorsia Pharmaceuticals Ltd | Alkoksi-pakeistieji piridinilo dariniai kaip lpa1 receptoriaus antagonistai ir jų panaudojimas fibrozės gydymui |
| CN109942576B (zh) * | 2019-03-07 | 2020-09-11 | 上海工程技术大学 | Irbinitinib及中间体的制备方法 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352991B1 (en) * | 1997-01-08 | 2002-03-05 | Wayne State University | 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents |
| ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
| AU2002303892A1 (en) | 2001-05-30 | 2002-12-09 | Jingrong Cui | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| KR100883731B1 (ko) | 2001-06-22 | 2009-02-12 | 기린 파마 가부시끼가이샤 | 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물 |
| US6790852B2 (en) * | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| ATE477811T1 (de) | 2002-10-03 | 2010-09-15 | Neuropharmacology Services Llc | Oxytocin zur behandlung von autismus und asperger-syndrom |
| CN103265477B (zh) * | 2003-02-26 | 2017-01-11 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| EP1473043A1 (en) | 2003-04-29 | 2004-11-03 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis |
| US20060009493A1 (en) | 2003-07-02 | 2006-01-12 | Sugen, Inc. | Indolinone hydrazides as c-Met inhibitors |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
| US7250417B2 (en) | 2003-07-02 | 2007-07-31 | Sugen Inc. | Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors |
| US20070213374A1 (en) | 2003-07-07 | 2007-09-13 | Merck Patent Gmbh | Malonamide Derivatives |
| DE602004012578T2 (de) | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
| JP4638436B2 (ja) | 2003-09-26 | 2011-02-23 | エグゼリクシス， インコーポレイテッド | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| US20070270421A1 (en) * | 2004-02-27 | 2007-11-22 | Tomohiro Matsushima | Novel pyridine Derivative and Pyrimidine Derivative (1) |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US7972601B2 (en) | 2004-05-11 | 2011-07-05 | The Regents Of The University Of California | Method of promoting delivery of an antioxidant agent to a cell expression neuroligin |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2572331A1 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| WO2006060318A2 (en) * | 2004-11-30 | 2006-06-08 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| SI1889836T1 (sl) * | 2005-08-24 | 2013-10-30 | Eisai R&D Management Co., Ltd. | Nov derivat piridina in derivat piridina (3) |
| SI1959955T1 (sl) | 2005-12-05 | 2011-02-28 | Pfizer Prod Inc | Postopek zdravljenja abnormalne celične rasti |
| JP5190365B2 (ja) * | 2006-08-23 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の塩またはその結晶およびそれらの製造方法 |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| CA2679602A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R&D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene |
| JP2009132660A (ja) * | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| JP2009203226A (ja) * | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
| US20100311972A1 (en) * | 2008-02-18 | 2010-12-09 | Mitsuo Nagai | Method for producing phenoxypyridine derivative |
-
2006
- 2006-08-21 SI SI200631634T patent/SI1889836T1/sl unknown
- 2006-08-21 EP EP06796594.7A patent/EP1889836B1/en active Active
- 2006-08-21 PL PL06796594T patent/PL1889836T3/pl unknown
- 2006-08-21 AU AU2006282456A patent/AU2006282456C1/en not_active Ceased
- 2006-08-21 RS RS20130334A patent/RS52902B/en unknown
- 2006-08-21 KR KR1020077026886A patent/KR100950737B1/ko active IP Right Grant
- 2006-08-21 CA CA2605854A patent/CA2605854C/en not_active Expired - Fee Related
- 2006-08-21 CN CN200680021939XA patent/CN101198590B/zh not_active Expired - Fee Related
- 2006-08-21 NZ NZ566793A patent/NZ566793A/en not_active IP Right Cessation
- 2006-08-21 BR BRPI0616799A patent/BRPI0616799B8/pt not_active IP Right Cessation
- 2006-08-21 WO PCT/JP2006/316331 patent/WO2007023768A1/ja active Application Filing
- 2006-08-21 MY MYPI20071922A patent/MY140873A/en unknown
- 2006-08-21 RU RU2008110932/04A patent/RU2362771C1/ru active
- 2006-08-21 TW TW095130665A patent/TWI377198B/zh not_active IP Right Cessation
- 2006-08-21 ES ES06796594T patent/ES2424651T3/es active Active
- 2006-08-21 JP JP2007532099A patent/JP4077028B2/ja not_active Expired - Fee Related
- 2006-08-21 PT PT67965947T patent/PT1889836E/pt unknown
- 2006-08-21 DK DK06796594.7T patent/DK1889836T3/da active
- 2006-08-23 US US11/508,322 patent/US7855290B2/en not_active Expired - Fee Related
- 2006-08-23 JO JO2006280A patent/JO2925B1/en active
-
2007
- 2007-11-06 ZA ZA200709572A patent/ZA200709572B/xx unknown
-
2008
- 2008-01-08 IL IL188670A patent/IL188670A/en active IP Right Grant
- 2008-01-24 NO NO20080460A patent/NO20080460L/no not_active Application Discontinuation
- 2008-09-11 HK HK08110122.2A patent/HK1114612A1/xx not_active IP Right Cessation
-
2009
- 2009-09-14 US US12/558,982 patent/US8288538B2/en active Active
-
2013
- 2013-07-31 HR HRP20130719TT patent/HRP20130719T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1114612A1 (en) | Pyridine derivative and pyrimidine derivative (3) | |
| IL176806A0 (en) | Novel pyridine derivative and pyrimidine derivative (2) | |
| EP1724267A4 (en) | PYRIMIDINE DERIVATIVE | |
| ZA200703912B (en) | 3-arylamino pyridine derivatives | |
| AP2007003887A0 (en) | Pyridine derivatives | |
| EP1847541A4 (en) | CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF | |
| EP1741703A4 (en) | PYRIDONE DERIVATIVE | |
| HK1120269A1 (en) | Pyrimidine derivatives | |
| EP1831170A4 (en) | SUBSTITUTED AMINOPYRIDINES AND THEIR USE | |
| IL185280A0 (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
| GB0525080D0 (en) | Pyrimidine derivatives | |
| GB0525083D0 (en) | Pyrimidine derivatives | |
| IL181386A0 (en) | Pyrimidine derivatives | |
| IL186939A0 (en) | Pyrimidine derivatives and their use as | |
| IL183706A0 (en) | 2,4(4,6) pyrimidine derivatives | |
| EP1877068A4 (en) | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE | |
| GB0415364D0 (en) | Pyrimidine derivatives | |
| HK1104553A1 (en) | Pyrimidine derivatives | |
| EP1820797A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVE | |
| GB0525081D0 (en) | Pyrimidine derivatives | |
| TWI349005B (en) | Malonamide derivatives | |
| EP1951681A4 (en) | NEW 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| GB0415367D0 (en) | Pyrimidine derivatives | |
| HK1164868A1 (zh) | 取代的吡啶衍生物 | |
| GB0416524D0 (en) | Pyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170821 |